Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Blood

Volumn 123, Issue 4, 2014, Pages 554-561

  Laszlo, George S ^a   Gudgeon, Chelsea J ^a   Harrington, Kimberly H ^a   Dell'Aringa, Justine ^b   Newhall, Kathryn J ^b   Means, Gary D ^b   Sinclair, Angus M ^c   Kischel, Roman ^d   Frankel, Stanley R ^c   Walter, Roland B ^a,e,f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b AMGEN INC   (United States)

^c AMGEN INC   (United States)

^d Amgen Research GmbH   (Germany)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMG 330; ANTILEUKEMIC AGENT; AZACITIDINE; BISPECIFIC ANTIBODY; BREAST CANCER RESISTANCE PROTEIN; CD3 ANTIBODY; CD33 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN; PANOBINOSTAT; UNCLASSIFIED DRUG; ANTIBODY; CD133 ANTIGEN; CD3 ANTIGEN; ENZYME INHIBITOR; GLYCOPROTEIN; HYDROXAMIC ACID; INDOLE DERIVATIVE; LEUKOCYTE ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CD33 GENE; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVITY; DRUG CYTOTOXICITY; EPIGENETICS; GENE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TARGET CELL; WILD TYPE; CELL STRAIN HL 60; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; METABOLISM; MONONUCLEAR CELL; TUMOR CELL LINE;

ANTIBODIES; ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ANTIGENS, CD3; AZACITIDINE; CELL LINE, TUMOR; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; GLYCOPROTEINS; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES;

EID: 84897018823     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-527044     Document Type: Article

References (43)

1. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26): 6198-6208.
2. Cowan AJ, Laszlo GS, Estey EH, Walter RB. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed). 2013;18(4):1311-1334.
3. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
4. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012; 30(32):3924-3931.
5. Castaigne S, Pautas C, Terré C, et al Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
6. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941-4944.
7. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opin Biol Ther. 2011;11(7):843-853.
8. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17(3):385-392.
9. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
10. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26):5185-5187.
11. Aigner M, Feulner J, Schaffer S, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia. 2013;27(5):1107-1115.
12. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466-1473. (Pubitemid 36988058)
13. Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood. 2004;103(11):4276-4284. (Pubitemid 38685374)
14. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105(3):1295-1302. (Pubitemid 40170906)
15. Walter RB, Raden BW, Thompson J, et al. Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells. Leukemia. 2004;18(11): 1914-1917. (Pubitemid 39530028)
16. Mortland L, Alonzo TA, Walter RB, et al. Clinical significance of CD33 nonsynonymous singlenucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013;19(6): 1620-1627.
17. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9(3):478-490.
18. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97(10):3197-3204.
19. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14(8):1436-1443. (Pubitemid 30601355)
20. Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood. 1981;57(6):1068-1073. (Pubitemid 11050810)
21. Fialkow PJ, Singer JW, Raskind WH, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987;317(8):468-473. (Pubitemid 17131352)
22. Bernstein ID, Singer JW, Andrews RG, et al. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest. 1987;79(4): 1153-1159. (Pubitemid 17065497)
23. Bernstein ID, Singer JW, Smith FO, et al. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood. 1992;79(7):1811-1816.
24. Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086-4092. (Pubitemid 41775913)
25. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8(4):521-534. (Pubitemid 14051256)
26. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67(4):1048-1053. (Pubitemid 16116418)
27. Pollard JA, Alonzo TA, Loken M, et al. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012;119(16):3705-3711.
28. van der Velden VH, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia. 2004;18(5):983-988. (Pubitemid 38714624)
29. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004;104(7):1940-1951. (Pubitemid 39297842)
30. Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia. 2007; 21(6):1172-1176. (Pubitemid 46831804)
31. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98(4):988-994.
32. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood. 2007;109(10):4168-4170. (Pubitemid 46743379)
33. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4): 275-284. (Pubitemid 40488633)
34. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83(8):1084-1103.
35. Lesley J, Schulte R, Woods J. Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments. Exp Cell Res. 1989;182(1):215-233. (Pubitemid 19123468)
36. Mellman I, Plutner H, Ukkonen P. Internalization and rapid recycling of macrophage Fc receptors tagged with monovalent antireceptor antibody: possible role of a prelysosomal compartment. J Cell Biol. 1984;98(4):1163-1169.
37. ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia. 2007; 21(2):248-252. (Pubitemid 46158116)
38. Kurimoto M, Matsuoka H, Hanaoka N, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2013;27(1): 233-235.
39. Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20(12): 2093-2101. (Pubitemid 44782834)
40. Garcia-Manero G. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Pract Res Clin Haematol. 2012; 25(4):427-435.
41. Quintás-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011;25(2): 226-235.
42. Thomas X. DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. Expert Opin Drug Discov. 2012;7(11):1039-1051.
43. Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Adv Exp Med Biol. 2013;754: 253-283.